BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"supportive care" Keyword-tagged Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Medical cannabis is effective for cancer-related pain: Quebec Cannabis Registry results | Aprikian S; Kasvis P; Vigano M; Hachem Y; Canac-Marquis M; Vigano A; | 37130724 PERFORM |
| 2 | Cancer Survivors' Evolving Perceptions of a New Supportive Virtual Program | Robb A; Brown TL; Durand A; Loiselle CG; | 36354724 PSYCHOLOGY |
| Title: | Medical cannabis is effective for cancer-related pain: Quebec Cannabis Registry results | ||||
| Authors: | Aprikian S, Kasvis P, Vigano M, Hachem Y, Canac-Marquis M, Vigano A | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/37130724/ | ||||
| DOI: | 10.1136/spcare-2022-004003 | ||||
| Publication: | BMJ supportive & palliative care | ||||
| Keywords: | cancer; pain; supportive care; symptoms and symptom management; | ||||
| PMID: | 37130724 | Category: | Date Added: | 2023-05-03 | |
| Dept Affiliation: |
PERFORM
1 School of Medicine, Royal College of Surgeons, Dublin, Ireland. 2 Medical Cannabis Program in Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, Quebec, Canada. 3 McGill Nutrition and Performance Laboratory, Montreal, Quebec, Canada. 4 Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, Quebec, Canada. 5 Department of Science, McGill University, Montreal, Quebec, Canada. 6 Department of Internal Medicine, Harvard Medical School, Boston, Massachusetts, USA. 7 Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. 8 Medical Cannabis Program in Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, Quebec, Canada antonio.vigano@mcgill.ca. 9 Division of Supportive and Palliative Care, McGill University Health Centre, Montreal, Quebec, Canada. |
||||
Description: |
Objectives: To evaluate the safety and effectiveness of medical cannabis (MC) in reducing pain and concurrent medications in patients with cancer. Methods: This study analysed data collected from patients with cancer who were part of the Quebec Cannabis Registry. Brief Pain Inventory (BPI), revised Edmonton Symptom Assessment System (ESAS-r) questionnaires, total medication burden (TMB) and morphine equivalent daily dose (MEDD) recorded at 3-month, 6-month, 9-month and 12-month follow-ups were compared with baseline values. Adverse events were also documented at each follow-up visit. Results: This study included 358 patients with cancer. Thirteen out of 15 adverse events reported in 11 patients were not serious; 2 serious events (pneumonia and cardiovascular event) were considered unlikely related to MC. Statistically significant decreases were observed at 3-month, 6-month and 9-month follow-up for BPI worst pain (5.5±0.7 baseline, 3.6±0.7, 3.6±0.7, 3.6±0.8; p<0.01), average pain (4.1±0.6 baseline, 2.4±0.6, 2.3±0.6, 2.7±0.7; p<0.01), overall pain severity (3.7±0.5 baseline, 2.3±0.6, 2.3±0.6, 2.4±0.6; p<0.01) and pain interference (4.3±0.6 baseline, 2.4±0.6, 2.2±0.6, 2.4±0.7, p<0.01). ESAS-r pain scores decreased significantly at 3-month, 6-month and 9-month follow-up (3.7±0.6 baseline, 2.5±0.6, 2.2±0.6, 2.0±0.7, p<0.01). THC:CBD balanced strains were associated with better pain relief as compared with THC-dominant and CBD-dominant strains. Decreases in TMB were observed at all follow-ups. Decreases in MEDD were observed at the first three follow-ups. Conclusions: Real-world data from this large, prospective, multicentre registry indicate that MC is a safe and effective complementary treatment for pain relief in patients with cancer. Our findings should be confirmed through randomised placebo-controlled trials. |
